LEGACY: A Multicenter Study Confirming TheraSphere™ as a Neoadjuvant or Standalone Therapy in Treating HCC

763 views
October 19, 2020
The LEGACY study is a multicenter, retrospective study demonstrating reproducible treatment outcomes across multiple centers and confirms published outcomes previously published in single center studies. This presentation provides background on the use of Y-90 glass microsphere to treat HCC, discusses results of the LEGACY study and recently published studies using Y-90 glass microspheres.
0 Comments
Login to view comments. Click here to Login